Overview

A Study of the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression

Status:
COMPLETED
Trial end date:
2024-10-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the Effectiveness and Safety of JS1-1-01 in Patients With Moderate to Severe Depression
Phase:
PHASE2
Details
Lead Sponsor:
Tasly Pharmaceutical Group Co., Ltd
Treatments:
Population Groups